肿瘤坏死因子拮抗剂治疗类风湿关节炎的效果分析

Clinical efficacy of tumor necrosis factor antagonist on rheumatoid arthritis

目的探讨肿瘤坏死因子拮抗剂治疗类风湿关节炎(RA)的临床效果。方法抽取2018年6月至2020年6月太原钢铁(集团)有限公司总医院收治的类风湿关节炎患者60例,按随机数字表法分为对照组和观察组,每组30例。对照组选择常规治疗,观察组在常规治疗基础上给予肿瘤坏死因子拮抗剂治疗。比较两组的临床效果及治疗前后症状与实验室指标。结果观察组总有效率(96.67%,29/30)高于对照组(73.33%,22/30),P<0.05。治疗前,两组关节压痛、关节肿胀、疼痛评分、晨僵时间比较差异未见统计学意义(P>0.05);治疗后,观察组关节压痛、关节肿胀数少于对照组,疼痛评分低于对照组,晨僵时间短于对照组(P<0.05)。治疗前,两组白细胞介素-17、类风湿因子、C反应蛋白水平及红细胞沉降率比较差异未见统计学意义(P>0.05);治疗后,观察组前述指标均低于对照组(P均<0.05)。结论常规治疗基础上联合肿瘤坏死因子拮抗剂治疗类风湿关节炎,可更好地改善患者的症状,降低白细胞介素-17、类风湿因子、C反应蛋白水平及红细胞沉降率。

Objective To investigate the clinical efficacy of tumor necrosis factors antagonist in the treatment of rheumatoid arthritis(RA).Methods Sixty patients with RA treated in the General Hospital of Taiyuan Iron and Steel(Group)Co.,Ltd.from June 2018 to June 2020 were selected,and they were divided into control group and observation group by random number table method,with 30 cases in each group.The control group was treated by routine treatment,and the observation group was treated with tumor necrosis factor antagonist based on routine treatment.The clinical effects,symptoms and laboratory indexes before and after treatment were compared between the two groups.Results The total effective rate in the observation group(96.67%,29/30)was higher than that in the control group(73.33%,22/30),P<0.05.Before treatment,there was no significant difference in joint tenderness,joint swelling,pain score and morning stiffness time between the two groups(P>0.05).After treatment,the number of joint tenderness and joint swelling in the observation group were less than those in the control group,the pain score was lower than that in the control group,and the morning stiffness time was shorter than that in the control group(P<0.05).Before treatment,there was no significant difference in the levels of interleukin-17,rheumatoid factor,C-reactive protein and erythrocyte sedimentation rate between the two groups(P>0.05);after treatment,the above indexes in the observation group were lower than those in the control group(all P<0.05).Conclusions Tumor necrosis factor antagonist combined with routine treatment in the treatment of RA,can better improve the symptoms of patients,and reduce the levels of interleukin-17,rheumatoid factor,C-reactive protein and erythrocyte sedimentation rate.